English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background  Neutralizing antibodies against nerve growth factor ( NGF ) are analgesic in rodent models, naturally occurring degenerative joint disease ( DJD ) pain in dogs, and chronic pain in humans.    Objectives  To evaluate the efficacy of a fully felinized anti‐ NGF  antibody ( NV ‐02) for the treatment of  DJD  pain and mobility impairment in cats.    Animals  Thirty‐four client‐owned cats with  DJD ‐associated pain and mobility impairment.    Methods  In a placebo‐controlled, pilot, masked clinical study, cats were randomized to a single treatment with  NV ‐02 (0.4 mg/kg  SC  [n = 11] or 0.8 mg/kg  SC  [n = 12]) or placebo (saline,  SC  [n = 11]). Activity was measured objectively. Additionally, owners completed clinical metrology instruments (client‐specific outcome measures [ CSOM ] and feline musculoskeletal pain index [ FMPI ]) on days 0 (screening), 14 (baseline), 35, 56, and 77. A repeated‐measures model was used to evaluate the objective activity data.    Results   NV ‐02 significantly increased objectively measured activity overall ( P  = .017) and at 2 ( P  = .035), 3 ( P  = .007), 4 ( P  = .006), 5 ( P  = .007), and 6 ( P  = .017) weeks after treatment.  CSOM  scores ( P  = .035) and pain ( P  = .024) showed a significant effect of treatment 3 weeks after administration. In the treatment group, 83% of the owners correctly identified the treatment administered compared with 45% of owners in the placebo group ( P  = .013). No treatment‐related adverse effects were identified.    Conclusions  These pilot data demonstrate a 6‐week duration positive analgesic effect of this fully felinized anti‐ NGF  antibody in cats suffering from  DJD ‐associated pain.

journal of veterinary internal medicine

A Feline‐Specific Anti‐Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study